Get started
BLUEBIRD BIO INC COM USD0.01 (REV SPT)BLUEBIRD BIO INC COM USD0.01 (REV SPT)BLUEBIRD BIO INC COM USD0.01 (REV SPT)

BLUEBIRD BIO INC COM USD0.01 (REV SPT)

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0HOH trade ideas

BLUE - long - possible bottom / gap play bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. This is not a financial advice! Couldn't find any catalyst that bothers me a bit to be honest. Biotechs are pretty hot recently We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work. 14.49% short float Block buys and Passive Stakes Keep an eye on 1.50 key level, needs to get broken for a further upmove. You could wait for an entry until 1.50 gets broken and watch the price action there. SL under 1.0 TP approx. 2.20 Most info on the chart. Trade carefully!
NASDAQ:BLUELong
by meitshels_smell_trades
2
BLUE – Short-Term Trade From The Depths Of Rock BottomNASDAQ:BLUE has dropped significantly from its $150 highs to its current price level around $1. I think BLUE is forming a dead cat bounce in the green support zone, and I can see a short-term swing up to the yellow trendline. The price has already rebounded quite a bit, I would look for an entry around the green support zone between $0.87 and $1.02. I can see BLUE reaching the yellow trendline at some point and there is a red resistance zone ahead. I think it will be difficult to reach the highs of the red resistance zone around $2.77. Instead, there is likely to be a slower move up towards the yellow trendline.
NASDAQ:BLUELong
by realchartchamp
BLUE- a biotechnology earnings penny stock LONGBLUE a week ago had a bull run to gain 90% in 5 days and then reversed into a standard Fibonacci retracement on the 30-minute chart, then in consolidation for a day or two getting support from the mean anchored VWAP. The last trading day was a quick rise with momentum in a bull flag. Earnings are coming. I will take another long trade on BLU into earnings. My target is 1.90 about the high of the prior trend up and below the second VWAP line above the mean. A tight stop loss at 1.53 ( below the flag's consolidation) will make it more likely the trade will be a 20% winner. I have taken call options strikng $1.50 for March 15th for $20 each. or a small loss of 2-3%
NASDAQ:BLUELong
by AwesomeAvani
Bluebird Bio (NASDAQ: BLUE) Posing Strong Bearish TrendBLUE is currently trading above its 50-day and 200-day simple moving averages (SMA), indicating a bullish trend. However, the 50-day SMA is below the 200-day SMA, forming a death cross pattern, which is a bearish signal. The 20-day exponential moving average (EMA) is also above the current price, acting as a resistance level. A break above the 20-day EMA could signal a continuation of the uptrend, while a break below the 50-day SMA could signal a reversal of the trend. Earnings and Revenue: The earnings per share (EPS) of BLUE is expected to decline by 37.50% in the current quarter (Dec 2023) and increase by 333.30% in the next quarter (Mar 2024). The EPS for the current year (2023) is estimated to be -$11.7, which is a 59.10% decrease from the previous year (2022). The EPS for the next year (2024) is projected to be -$8.6, which is an 26.50% increase from the current year2. The revenue of BLUE is expected to decrease by 3.10% in the current quarter (Dec 2023) and increase by 9.00% in the next quarter (Mar 2024). The revenue for the current year (2023) is estimated to be $289.2 million, which is a 0.80% decrease from the previous year (2022). The revenue for the next year (2024) is forecasted to be $313.6 million, which is a 8.40% increase from the current year. The technical analysis of BLUE shows that the stock is in a mixed trend, with some bullish and bearish signals. The stock is also facing low volatility and uncertain momentum. The earnings and revenue estimates suggest that the company is going through a challenging period, but might recover in the future.
NASDAQ:BLUEShort
by DEXWireNews
BLUE Bullish DivergenceOn Balance Volume has been (bullishly) diverging from price since May indicating that "smart money" has likely been accumulating. ADX is a level that implies a trend and D+ crossing D- indicates that it is bullish. Recently we see price test the .236 Fibonacci level on higher than average daily volume days after gapping up and possibly changing trend (higher low, with volume) Currently price sits at a possible double top, in the event that it cannot close above $4.05. The chart looks bullish if price can break the $4.05-$4.13 level, with volume. Support/Stop $3.50ish targets: $5.63, $7.26
NASDAQ:BLUELong
by Master_of_Fine_Charts
Trading bluebird bio to $6: Bluebird bio (BLUE) is a biotech company focused on developing and commercializing gene and cell therapies to treat genetic diseases. Lead asset LentiGlobin (Zynteglo) is approved in US and Europe for the treatment of transfusion-dependent thalassemia. Bluebird's LentiGlobin (lovo-cel) is also in pre-registrational stage for sickle cell disease. Bluebird is also right behind Crispr and Vertex in pursuit of a sickle cell approval. June 21st 2023: Lovo-cel is a potentially transformative one-time gene therapy for individuals living with sickle cell disease (SCD) ages 12 and older who have a history of vaso-occlusive events. It is specifically designed to treat the underlying cause of SCD through the addition of a functional gene that enables production of anti-sickling adult hemoglobin and is the most deeply studied gene therapy in development for this disease. The agency has set a Prescription Drug User Fee Act goal date of December 20, 2023.
NASDAQ:BLUELong
by KhanhC.Hoang
BLUE Biotechnology New Earnings Catalyst LONGBlueBird Bio / BLUE had an earnigns report this past week showing earnings for the firat time but revenue was far below analyst's projections. Price has appreciated 40% in the 4 weeks since earnings which is about 500% annualized. GO BLUE. On the daily chart, price was above VWAP and consolidating much of last fall then dropped this YTD until the earnings report of last week. An uptrend is seen after the earnings. This has been a significant reversal sustained over the past month with price rising above the support / demand zone below it. At present, price is one standard deviation below VWAP making it undervalued and ascending. I see this as a risky long trade like many biotechology penny stocks but with a decent probability of profit in consideration of a target of 6.15 which is the top of the long term high volume area. the stop loss is just below the POC line of the volume profile at 3.15 An entry at 4.62 ( limit order above SMA200 (redlne) would yield at profit of 1.50 with a risk of 0.48 making for a R:R of 3:1. Another earnings report is coming up this week. If it is favorable, BLUE could go parabolic to hit the target in a day or two. If not, it will be time to exit the trade.
NASDAQ:BLUELong
by AwesomeAvani
7
$BLUE - reversal play?$BLUE has been in down trend just recently formed a potential rounding bottom reversal. If price can break through $7.50 then $8 it can head to $11.75 area. $7.50 is an important resistance area and breaking through that would require quite a push from the bulls. Target 1 - $7.50 Target 2 - $8.00 Target 3 - $11.00 Risk - fail to get above $7.50. Retreat to $5 area. ---- Disclaimer: Not investment advice. If you like this post, follow me and subscribe to my posts for more technical analysis charts.
NASDAQ:BLUELong
by PaperBozz
3
BLUEbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent -thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. bluebird bio, Inc. has a strategic alliance with National Resilience, Inc. to research, development, and delivery of cell therapies. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
NASDAQ:BLUELong
by maverick1239
1
Bluebird Bio Inc 🧙bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates. Here you can see pipeline: Betibeglogene autotemcel (beti-cel) (LentiGlobin) - HGB-212 Northstar-3 Phase 3 updated at EHA June 11, 2021. 89% (32/36) of evaluable patients achieved transfusion independence (TI) and remain transfusion free (HGB-207, HGB-212) Betibeglogene autotemcel (beti-cel) (LentiGlobin) - HGB-207 Northstar-2 Phase 3 updated at EHA June 11, 2021. 89% (32/36) of evaluable patients achieved transfusion independence (TI) and remain transfusion free (HGB-207, HGB-212) Lenti-D (Elivaldogene Autotemcel / Eli-Cel) - ALD-102 Phase 2/3 updated data presented March 15, 2021. 90% of evaluable patients (27/30) alive and free of major functional disabilities at two years follow-up. Betibeglogene autotemcel (beti-cel) (LentiGlobin) BLA filing to be completed Betibeglogene autotemcel (beti-cel) (LentiGlobin) - HGB-206 Phase 1/2 trial temporarily suspended due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) - February 16, 2021. Clinical hold lifted June 7, 2021. Data to be presented by end of 2021. Lenti-D (Elivaldogene Autotemcel / Eli-Cel) - ALD-104 Phase 3 safety data to be presented at EBMT 2020. Noted two adverse events (out of 13 patients) of pancytopenia were considered possibly related to Lenti-D. Phase 3 trial placed on clinical hold - noted August 9, 2021. BLA filing due 2021 subject to resolution of the clinical hold. ABECMA (idecabtagene vicleucel) Phase 1 data presented at ASH 2020. bb21217 (CRB-402) Phase 1 data due by end of 2021. MGTA-145 and plerixafor Phase 2 trial to be initiated 4Q 2021. Betibeglogene autotemcel (beti-cel) (LentiGlobin) - (HGB-210) Phase 3 trial temporarily suspended due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) - February 16, 2021. Clinical hold lifted June 7, 2021.
NASDAQ:BLUELong
by yura_trades
LONG OPTION CALL - TRADE OF THE YEAR IF YOU ARE PATIENTGuys, Even with news this play IS HUGE just look at the position of this chart / downtrend and where it would pivot ON A MONTHLY CHART. I am entering this trade today on on call options for 3-4 months out. Stop loss is under all time low / may even add more at that point. Solid company. Regardless of news this looks like a big reveral coming. News: 2 MINUTES AGO | 7:00 AM CDT | BUSINESSWIRE bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease Stocks mentioned: BLUE RSI = dead DOJI candles MACD just waiting to cross Downtrend w/ Doji candles
NASDAQ:BLUELong
by DigitalData